Publications
Books Co-Edited
1. Bawa, R.: Nanomedicine Section Editor, Biomedical Engineering Handbook, 4th edition, CRC Press/Taylor Francis, , Boca Raton, 2012.
2. Bawa, R., J. D. Bronzino, D. R. Peterson (Editors): Nanomedicine: Principles and Practices, CRC Press/Taylor Francis, , Boca Raton, 2012.
3. Bawa, R. (Editor): Nanotechnology – Law, Business and Commercialization, Pan Stanford Publishing, Singapore, 2012.
4. Bawa, R., Audette, G. and Rubinstein, I. (Editors): Clinical Nanomedicine – From Bench to Bedside, Pan Stanford Series in Nanomedicine, Volume 1, Pan Stanford Publishing, Singapore, 2012.
Selected Publications
1. Bawa, R. (2011). The FDA and nanoregulation. WIRE’s Nanomedicine and Nanobiotechnology (invited).
2. Bawa, R.. (2012). Editorial: Silver nanoparticles as antimicrobials – miracle agents or toxins? Nanomedicine (in preparation)
3. Bawa, R. (2011). Regulating nanomedicine – Can the FDA handle it? Current Drug Delivery 8:227-234.
4. Bawa, R. (2010). The blood-brain barrier. In: D. H. Guston (editor). Encyclopedia of Nanoscience and Society, SAGE Publications, Inc., Thousand Oaks, CA, pages 54-55.
5. Bawa, R. (2010). Nanopharmaceuticals in medicine: The Present and the Future. In: C.W. Wagner (editor). Strategies and Technologies for a Sustainable Future. World Future Society, Bethesda, MD; pages 219-231.
6. Kanwar, J. R., R. R. Mohan, R. K. Kanwar, K. Roy and R. Bawa. (2010). Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine 5(9):1435-1445.
7. Bawa, R. (2010). Nanoenabled drugs. In: D. H. Guston (editor). Encyclopedia of Nanoscience and Society, SAGE Publications, Inc., Thousand Oaks, CA, pages 470-472.
8. Bawa, R. (2010). Patents. In: D. H. Guston (editor). Encyclopedia of Nanoscience and Society, SAGE Publications, Inc., Thousand Oaks, CA, pages 615-618.
9. Bawa, R. and S. Johnson. (2010). The ethical implications of nanomedicine must be considered. In: Longwith, J. (editor), Nanotechnology, Greenhaven Press, Farmington Hills, MI, pages187-197.
10. Bawa, R. (2009). Nanopharmaceuticals. In: D. Luscombe and P. D. Stonier (editors), Clinical Research Manual, 2nd edition, Euromed Communications, UK, Supplement 27, S27.1-S27.20. [Also published in: European Journal of Nanomedicine 3(1):34-39. 2010.]
11. Bawa, R. (2009). The Unither Conference - Recent Advances in Nanomedical Structures and Devices. Journal of Nanobioscience 3(2):67-72(6).
12. Bawa, R. (2009). Nanopharmaceuticals for drug delivery – A Review. Touch Briefings 6:122-127.
13. Bawa, R. (2009). NanoBiotech 2008: Exploring global advances in nanomedicine. Nanomedicine: NBM 5:5-7.
14. Bawa, R. (2009). Patenting inventions in bionanotechnology – A primer for scientists and lawyers. In: D. E. Reisner (editor). Bionanotechnology: Global Prospects, CRC Press, Boca Raton, FL 309-337.
15. Bawa, R. (2008). Nanoparticle-based therapeutics in humans: a survey. Nanotechnology Law & Business 5(2):135-155.
16. Bawa, R., S. Melethil, W. J. Simmons and D. Harris. (2008). Nanopharmaceuticals – patenting issues and FDA regulatory challenges. American Bar Association SciTech Lawyer 5(2):10-15.
17. Bawa, R. and S. Johnson. (2008). Emerging issues in nanomedicine and ethics In: F. Allhoff and P. Lin (editors), Nanotechnology & Society: Current and Emerging Ethical Issues, Springer, Dordrecht, 207-223.
18. Bawa, R. (2007). Special Report - Patents and nanomedicine. Nanomedicine 2(3):351-374.
19. Bawa, R. (2007). Pharma MedDevice 2007: Issues in nanodrug delivery and personalized medicine. Investigational Drugs 10(7):455-458.
20. Harris, D. and R. Bawa. (2007). The carbon nanotube patent landscape in nanomedicine: an expert opinion. Expert Opinion on Therapeutic Patents 17(9):1165-1174.
21. Bawa, R. (2007). Nanotechnology patent proliferation and the crisis at the US Patent Office. Albany Law Journal of Science and Technology 17(3):699-735.
22. Bawa, R. and S. Johnson. (2007). The ethical dimensions of nanomedicine. The Medical Clinics of North America 91(5):881–887.
23. Bawa, R. (2007). The future of nanomedicine. In: T. C. Mack (editor). Hopes and Visions for the 21st Century. World Future Society, Bethesda, MD; pages 266-283.
24. O’Neill, S., K. Hermann, M. Klein, J. Landes and R. Bawa. (2007). Broad claiming in nanotechnology patents: Is litigation inevitable? Nanotechnology Law and Business 4(1):595-606.
25. Bawa, R. (2010). The stem cell patent landscape: an expert opinion. Expert Opinion on Therapeutic Patents (in preparation)
26. Morrow, K.J., R. Bawa, and C. Wei. (2007). Recent advances in basic and clinical nanomedicine. The Medical Clinics of North America 91(5):805-843.
27. Bawa, R. (2006). Emerging issues and trends in nanotechnology patent law. Nanomedicine: NBM 2:280-281. (Abstract)
28. Bawa, R., S. R. Bawa, S. B. Maebius and C. Iyer. (2006). Bionanotechnology patents: challenges and
opportunities. In: J. D. Bronzino (editor). The Biomedical Engineering Handbook. 3rd edition, Tissue Engineering and Artificial Organs, CRC Press, Boca Raton, FL; pages 29-1 to 29-16.
29. Bawa, R. (2005). Patenting nanomedicine: a catalyst for commercialization? Small Times 5(8):16.
30. Bawa, R. (2005). Editorial Commentary - Will the nanomedicine “patent land grab” thwart commercialization? Nanomedicine: NBM 1:346-350.
31. Bawa, R., S. R. Bawa and S. Maebius. (2005). The nanotechnology patent ‘gold rush.’ Journal of Intellectual Property Rights 10:426-433.
32. Bawa, R., and S. R. Bawa. (2005). Protecting new inventions in nanomedicine. In: C. G. Wagner (editor). Foresight, Innovation, and Strategy: Towards a Wiser Future. World Future Society, Bethesda, MD; pages 31-44.
33. Bawa, R., S.R. Bawa, S. B. Maebius, T. Flynn, and C. Wei. (2005). Protecting new ideas and inventions in nanomedicine with patents. Nanomedicine: NBM 1(2):150-158.
34. D. Harris, J. Miller, R. Bawa, J. T. Cleveland, and S. O’Neill. (2004). Strategies for resolving patent disputes over nanoparticle drug delivery systems. Nanotechnology Law and Business 1(4):101-118.
35. Bawa, R. (2004). A comprehensive nanotechnology library in miniature: a review of the Springer Handbook of Nanotechnology. Nanotechnology Law and Business 1(3):341-343.
36. Bawa, R. (2004). Nanotechnology patenting in the U.S. Nanotechnology Law and Business 1(1):31-50.
37. Bawa, R. (2004). Nanotechnology patents and the U.S. Patent Office. Small Times 4(1):IP8.
38. Bawa, R. (2001). Patenting HIV/AIDS Inventions. USPTO Today 2(11/12):20-23.
39. Bawa, R. (1999). World AIDS day 1998 calls for youth awareness and participation. Patent & Trademark Office Pulse 7(2):2 and 10.
40. Bawa, R. (1997). The biology and patents of HIV/AIDS. Patent & Trademark Office Pulse 5(6):6-9.
41. Bawa, S.R., R. Bawa, and H.K. Bains. (1993). Peanut agglutinin receptors in the epididymal spermatozoa of the palm squirrel (Funambulus penanti). In: G.W. Bailey et al. (editors). Proc. 51st Annual Meeting of the Microscopy Society of America, San Francisco Press, Inc., pp. 324-325.
42. Bawa, S.R., R. Bawa, and H.K. Bains. (1993). Electron microscopy of the changes in the sperm head
curvature of the palm squirrel (Funambulus penanti). In: G.W. Bailey et al. (editors). Proc. 51st Annual Meeting of the Microscopy Society of America, San Francisco Press, Inc., pp. 334-335.
43. Bawa, R. (1991). Purification and partial characterization of a potassium transport protein from mammalian mitochondria. Dissertation Abstracts International 52(3):1401B. (Abstract)
44. Diwan, J.J., R. Paliwal, E. Kaftan, and R. Bawa. (1990). A mitochondrial protein fraction catalyzing transport of the K+ analog TI+. FEBS Letters 273:215-218.
45. Bawa, R., and J.J. Diwan. (1988). Uptake of cationic anticancer drugs and polyamines by mammalian mitochondria. Biophysical Journal 53:375a. (Abstract)
46. Diwan, J.J., H.H. Yune, R. Bawa, T. Haley, and C.A. Mannella. (1988). Enhanced uptake of spermidine and methlyglyoxal-bis(guanylhydrazone) by rat liver mitochondria following outer membrane lysis. Biochemical Pharmacology 37:957-961.
47. Diwan, J.J., C.A. Mannella, T. Haley, R. Bawa, and H.H. Yune. (1987). Outer membrane lysis increases accessibility of cationic drugs to the inner mitochondrial membrane. In: C.H. Kim et al. (editors). Advances in Membrane Biochemistry and Bioenergetics, Plenum Press, New York, pp. 409-416.
48. Singal, P.K., S.R. Bawa, R. Darbari, R. Kaur, C.M.R. Deally, and R. Bawa. (1987). Effects of chronic Adriamycin treatment of rats on myocardial lipid histochemistry. In: N.S. Dhalla et al. (editors). Pathophysiology of Heart Disease, Martinus Nijhoff Publishing, Boston, Dordrecht and Lancaster, pp. 297-309.
49. Bawa, S.R., R. Darbari, R. Kaur, R. Bawa, and P. K. Singal. (1987). Myocardial lipid changes during adriamycin-induced cardiomyopathy: A histochemical study. Journal of Molecular and Cellular Cardiology 18:11. (Abstract)
50. Bawa, S.R., P.K. Singal, R. Darbari, R. Kaur, and R. Bawa. (1986). Adriamycin treated cardiac muscle – An electron microscope study. In: Proceedings of the XIth International Congress on Electron Microscopy, Kyoto, Japan, pp. 3525-2526.
